Skip to main content
Terug
Watch Compare

Immix Biopharma, Inc.

Datakwaliteit: 100%
IMMX
NASDAQ Manufacturing Chemicals
€ 9,96
▼ € 0,08 (-0,80%)
6 months return
—
Momentum
Neutral
ROE
-455,78%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-455,78%
Onder sectorgemiddelde (-54,47%)
ROIC-318,61%
Net Margin-147,19%
Op. Margin-149,78%

Veiligheid

Debt / Equity
N/A
Current Ratio1,53
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-17,37 | -13,80
Onder sectorgemiddelde (-1,50)
P/B Ratio61,86
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -24,66 M
Capital efficient — spends only 3,66% of revenue on capex

Price History

Financiële Trends

Koersdoel Analisten

5 analisten
Strong Buy
+76.3%
upside to target
Huidig
€ 9,96
Consensus Target
€ 17,56
€ 14,80
Laag
€ 23,00
Hoog
Vooruitzicht
Forward K/W
-13,80
Forward WPA
-€ 0,73
Omzet Sch.
56,42 M

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,21 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,15 -€ 0,22 -€ 0,24 -€ 0,28 — —
Estimate -€ 0,23 -€ 0,16 -€ 0,19 -€ 0,16 -€ 0,21 -€ 0,21
Verrassing +34,78% -37,50% -26,32% -75,00% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 0,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -455,78% · Net Margin: -147,19%
Revenue (TTM) 20,00 M Net Income (TTM) -29,44 M
ROE -455,78% ROA -164,85%
Gross Margin N/A Operating Margin -149,78%
Net Margin -147,19% Free Cash Flow (TTM) -24,66 M
ROIC -318,61% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 1,53
Debt / Equity N/A Current Ratio 1,53
Interest Coverage N/A Asset Turnover 1,12
Working Capital 5,73 M Tangible Book Value 8,26 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -17,37 · EV/EBITDA: N/A
P/E Ratio -17,37 Forward P/E -13,80
P/B Ratio 61,86 P/S Ratio 25,57
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 9,06 Fwd Earnings Yield N/A
FCF Yield -4,82%
Market Cap 511,30 M Enterprise Value 495,35 M

Per Share

EPS: -0,89 · FCF/Share: -0,47
EPS (Diluted TTM) -0,89 Revenue / Share 0,38
FCF / Share -0,47 OCF / Share -0,45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 83,78% · CapEx/Rev: 3,66%
CapEx / Revenue 3,66% FCF Conversion 83,78%
SBC-Adj. FCF -27,27 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 20,00 M 20,00 M 20,00 M — —
Net Income -29,44 M -21,61 M -15,43 M -8,23 M -24,38 M
EPS (Diluted) -0,89 -0,76 -0,89 — —
Gross Profit — — — — —
Operating Income -29,96 M -22,67 M -16,14 M -8,22 M -1,35 M
EBITDA — — — — —
R&D Expenses 16,26 M 11,29 M 8,74 M 4,20 M 126.527,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 497,0 497,0 179.853,0
Income Tax 37.724,0 41.037,0 26.415,0 10.268,0 6.013,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 104,84 M 22,95 M 19,93 M 14,91 M 18,19 M
Total Liabilities 11,04 M 9,70 M 3,72 M 1,75 M 202.039,0
Shareholders' Equity 93,80 M 13,25 M 16,41 M 13,16 M 17,99 M
Total Debt — — — — —
Cash & Equivalents 93,93 M 17,68 M 17,51 M 13,44 M 17,64 M
Current Assets 101,24 M 20,20 M 19,79 M 14,90 M 18,19 M
Current Liabilities 10,11 M 8,69 M 3,72 M 1,27 M 202.039,0

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -17,4 -1,5
P/B 61,9 1,6
ROE % -455,8 -54,5
Net Margin % -147,2 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3